Marianne Hamilton - Karo Pharma Director
| KARBFDelisted Stock | USD 5.25 0.00 0.00% |
Director
Ms. Marianne Hamilton no longer serves as Independent Director of Karo Pharma Aktiebolag effective as of February 14, 2019. She has held the position since May 11, 2017. She holds Bachelor of Arts degree from Stockholms universitet. She was HR Director and SVP at Atlas Copco AB, as well as Board Member of Meda AB, Connecta AB and Alecta. She is Board Member of KeyBroker and Lundsbergs Boarding School, as well as Member of the Swedish Remuneration Academy and Advisory Board of the Stockholm Business School. since 2017.
| Age | 71 |
| Tenure | 7 years |
| Phone | 46 1 03 30 23 10 |
| Web | https://www.karopharma.com |
Karo Pharma Management Efficiency
Karo Pharma's management efficiency ratios could be used to measure how well Karo Pharma manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 5.58 B in total debt with debt to equity ratio (D/E) of 1.06, which is about average as compared to similar companies. Karo Pharma AB has a current ratio of 2.66, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Karo Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Karo Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Karo Pharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Karo to invest in growth at high rates of return. When we think about Karo Pharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Rodolfo Garza | Volaris | 61 | |
| Jimmy Zadigue | Volaris | 47 | |
| Robert Eckert | Amgen Inc | 63 | |
| Frank Biondi | Amgen Inc | 70 | |
| Greg Garland | Amgen Inc | 56 | |
| Armando Furio | Volaris | N/A | |
| Andrew Roberts | SkyWest | 57 | |
| Renato Salomone | Volaris | N/A | |
| Charles Holley | Amgen Inc | 61 | |
| John Teets | Air Transport Services | 45 | |
| Gene Burleson | SunLink Health Systems | 77 | |
| Ellen Kullman | Amgen Inc | 62 | |
| Robert Williams | Amgen Inc | 69 | |
| Stanley Pace | Volaris | 66 | |
| Jorge Barroso | Volaris | 65 | |
| Joaquin Deneke | Volaris | 69 | |
| David Baltimore | Amgen Inc | 78 | |
| Henry Eyring | SkyWest | 54 | |
| Keith Smith | SkyWest | 57 | |
| Harry Krensky | Volaris | 56 | |
| Roberto Avila | Volaris | 64 | |
Management Performance
| Return On Equity | -0.0269 | |||
| Return On Asset | 0.0017 |
Karo Pharma AB Leadership Team
Elected by the shareholders, the Karo Pharma's board of directors comprises two types of representatives: Karo Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Karo. The board's role is to monitor Karo Pharma's management team and ensure that shareholders' interests are well served. Karo Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Karo Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Blom, CEO | ||
| Jon Johnsson, Chief Officer | ||
| Anna Hale, Chief Officer | ||
| Lisa Westerdahl, VP Communications | ||
| Sofia Kyhlstedt, VP Affairs | ||
| Erika Henriksson, Director | ||
| Anders Lonner, Chairman of the Board | ||
| Jonathan Kimber, VP Operations | ||
| Marianne Hamilton, Director | ||
| Maria Sjoberg, Vice President Chief Scientific Officer, responsible for Preclinical Research and Development | ||
| Thomas Kraft, Country Manager Norway | ||
| Vesa Koskinen, Director | ||
| Eva Saers, Director | ||
| Simen NybergHansen, Managing Director Norway | ||
| Asa Riisberg, Director | ||
| Thomas Hedner, Director | ||
| SIMON NybergHansen, Managing Norway | ||
| PerAnders Johansson, Independent Director | ||
| Jean Lycke, Director | ||
| Per Johansson, Member of the Board | ||
| MatsOlof Wallin, CFO | ||
| Carl Lindgren, Vice President Business Development | ||
| Matt Roberts, Chief Officer | ||
| Henrik Palm, CFO | ||
| Christoffer Lorenzen, Chief Officer | ||
| Fredrik Thorsen, Head Ecommerce | ||
| Bo Hansen, Director | ||
| Ulf Mattsson, Interim CEO | ||
| Hakan Astrom, Director | ||
| Karin Lindberg, Head Organization | ||
| Goran Wessman, Director | ||
| Bo Carlsson, Member of the Board, Employee Representative |
Karo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Karo Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0269 | |||
| Return On Asset | 0.0017 | |||
| Profit Margin | (0.05) % | |||
| Current Valuation | 2.34 B | |||
| Shares Outstanding | 273.26 M | |||
| Shares Owned By Insiders | 1.26 % | |||
| Shares Owned By Institutions | 88.29 % | |||
| Price To Earning | 262.50 X | |||
| Price To Book | 1.89 X | |||
| Price To Sales | 4.49 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Karo Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Karo Pharma's short interest history, or implied volatility extrapolated from Karo Pharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Karo Pharma AB information on this page should be used as a complementary analysis to other Karo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Karo Pink Sheet
If you are still planning to invest in Karo Pharma AB check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karo Pharma's history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |